Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dally

Showing results (521-530 of 579) with videos related to

Pageof 58
Sort By:
Clinical and Vaccine Immunology : CVI|January 25, 2013
Safety and immunogenicity of DNA prime and modified vaccinia ankara virus-HIV subtype C vaccine boost in healthy adultsPeter Hayes, Jill Gilmour, Andrea von Lieven, et al.
The Journal of Infectious Diseases|February 6, 2010
Viral inhibition assay: a CD8 T cell neutralization assay for use in clinical trials of HIV-1 vaccine candidatesAggeliki Spentzou, Philip Bergin, Dilbinder Gill, et al.
Human Vaccines & Immunotherapeutics|December 31, 2013
Long-term follow-up of study participants from prophylactic HIV vaccine clinical trials in AfricaClaudia Schmidt, Walter Jaoko, Gloria Omosa-Manyonyi, et al.
Plos One|February 19, 2013
Safety and immunogenicity of DNA and MVA HIV-1 subtype C vaccine prime-boost regimens: a phase I randomised Trial in HIV-uninfected Indian volunteersSanjay Mehendale, Madhuri Thakar, Seema Sahay, et al.
Bioorganic & Medicinal Chemistry Letters|October 10, 2001
Discovery of heterocyclic ureas as a new class of raf kinase inhibitors: identification of a second generation lead by a combinatorial chemistry approachR A Smith, J Barbosa, C L Blum, et al.
Blood Advances|December 5, 2024
Trial eligibility, treatment patterns, and outcome for venetoclax-based therapy in AML: a prospective cohort studyOfir Wolach, Itai Levi, Boaz Nachmias, et al.
Plos One|August 8, 2015
A Phase I Double Blind, Placebo-Controlled, Randomized Study of the Safety and Immunogenicity of Electroporated HIV DNA with or without Interleukin 12 in Prime-Boost Combinations with an Ad35 HIV Vaccine in Healthy HIV-Seronegative African AdultsJuliet Mpendo, Gaudensia Mutua, Julien Nyombayire, et al.
Vaccine|September 25, 2008
Lessons from IAVI-006, a phase I clinical trial to evaluate the safety and immunogenicity of the pTHr.HIVA DNA and MVA.HIVA vaccines in a prime-boost strategy to induce HIV-1 specific T-cell responses in healthy volunteersA Guimarães-Walker, N Mackie, S McCormack, et al.
The Lancet. Infectious Diseases|August 19, 2018
Safety and immunogenicity of a pentavalent meningococcal conjugate vaccine containing serogroups A, C, Y, W, and X in healthy adults: a phase 1, single-centre, double-blind, randomised, controlled studyWilbur H Chen, Kathleen M Neuzil, C Rebecca Boyce, et al.
Journal of Clinical Medicine|September 28, 2023
MDS-Related Anemia Is Associated with Impaired Quality of Life but Improvement Is Not Always Achieved by Increased Hemoglobin LevelYael Haring, Noa Goldschmidt, Shaimaa Taha, et al.
Pageof 58

Showing results (521-530 of 579) with videos related to

Sort By:
Pageof 58
Clinical and Vaccine Immunology : CVI|January 25, 2013
Safety and immunogenicity of DNA prime and modified vaccinia ankara virus-HIV subtype C vaccine boost in healthy adultsPeter Hayes, Jill Gilmour, Andrea von Lieven, et al.
The Journal of Infectious Diseases|February 6, 2010
Viral inhibition assay: a CD8 T cell neutralization assay for use in clinical trials of HIV-1 vaccine candidatesAggeliki Spentzou, Philip Bergin, Dilbinder Gill, et al.
Human Vaccines & Immunotherapeutics|December 31, 2013
Long-term follow-up of study participants from prophylactic HIV vaccine clinical trials in AfricaClaudia Schmidt, Walter Jaoko, Gloria Omosa-Manyonyi, et al.
Plos One|February 19, 2013
Safety and immunogenicity of DNA and MVA HIV-1 subtype C vaccine prime-boost regimens: a phase I randomised Trial in HIV-uninfected Indian volunteersSanjay Mehendale, Madhuri Thakar, Seema Sahay, et al.
Bioorganic & Medicinal Chemistry Letters|October 10, 2001
Discovery of heterocyclic ureas as a new class of raf kinase inhibitors: identification of a second generation lead by a combinatorial chemistry approachR A Smith, J Barbosa, C L Blum, et al.
Blood Advances|December 5, 2024
Trial eligibility, treatment patterns, and outcome for venetoclax-based therapy in AML: a prospective cohort studyOfir Wolach, Itai Levi, Boaz Nachmias, et al.
Plos One|August 8, 2015
A Phase I Double Blind, Placebo-Controlled, Randomized Study of the Safety and Immunogenicity of Electroporated HIV DNA with or without Interleukin 12 in Prime-Boost Combinations with an Ad35 HIV Vaccine in Healthy HIV-Seronegative African AdultsJuliet Mpendo, Gaudensia Mutua, Julien Nyombayire, et al.
Vaccine|September 25, 2008
Lessons from IAVI-006, a phase I clinical trial to evaluate the safety and immunogenicity of the pTHr.HIVA DNA and MVA.HIVA vaccines in a prime-boost strategy to induce HIV-1 specific T-cell responses in healthy volunteersA Guimarães-Walker, N Mackie, S McCormack, et al.
The Lancet. Infectious Diseases|August 19, 2018
Safety and immunogenicity of a pentavalent meningococcal conjugate vaccine containing serogroups A, C, Y, W, and X in healthy adults: a phase 1, single-centre, double-blind, randomised, controlled studyWilbur H Chen, Kathleen M Neuzil, C Rebecca Boyce, et al.
Journal of Clinical Medicine|September 28, 2023
MDS-Related Anemia Is Associated with Impaired Quality of Life but Improvement Is Not Always Achieved by Increased Hemoglobin LevelYael Haring, Noa Goldschmidt, Shaimaa Taha, et al.
Pageof 58